US Week 5 Pneumonia & Influenza Death Rate Is 9.0%



	Home	Founder	What's New	In The News	Consulting



H1N1 Consulting Paradigm Shift Viral Evolution Intervention Monitoring Vaccine Screening Vaccine Development Expression Profiling Drug Discovery Custom Therapies Patents	Audio:Nov30 Dec20 Jan17 Jan24 twitter Commentary US Week 5 Pneumonia & Influenza Death Rate Is 9.0% Recombinomics Commentary 21:00 February 7, 2013 Tomorrow’s week 5 FluView will report a Pneumonia and Influenza (P&I) Death Rate of 9.0%, which is 0.4% lower than week 4, which was 0.4% below the peak of 9.8% in week 3. As seen in the above week 4 graph, the week 5 rate of 9.0% is still 1.5% above the epidemic threshold. It represents the fourth week in a row when the rate was at least 1 % above the epidemic threshold, and the third week in a row when the rate was 9% or higher. This high level has produce a list of 26 cities which reported at least 10 P&I and a death rate of at least 10% as seen in the week 5 list below. Once again the Pacific region has the highest rate (14.9%), led by the 47 death in Los Angeles which produced at rate of 19.9%. The high rates in the west contributed to the list of 14 pediatric deaths reported in week 5. The pediatric deaths are a trailing indicator, and the 14 deaths in week 5 represent the highest number reported this season. Regions PACIFIC 14.9% NEW ENGLAND 11.8% WN CENTRAL 10.8% Cities (26) Worchester MA 21.3% Los Angeles 19.9% Rockford IL 18.8% Tulsa OK 16.7% Knoxville TN 16.4% Fort Wayne IN 16.3% Des Moines IA 15.2% Grand Rapids MI 14.9% Wichita KS 14.4% San Francisco CA 12.9% Salt Lake City UT 12.5% Fresno CA 12.2% Kansas City MO 12.2% Charlotte NC 12.1% Chattanooga TN 11.9% Honolulu HI 11.5% San Diego CA 11.4% Baltimore MD 11.4% Sacramento CA 11.4% Washington DC 10.9% Indianapolis IN 10.8% San Jose CA 10.5% Milwaukee WI 10.5% Rochester NY 10.2% Memphis TN 10.0% San Antonio TX 10.0% Media Link Recombinomics Presentations Recombinomics Publications Recombinomics Paper at Nature Precedings

Home | Founder | What's New | In The News | Contact Us